Ibrutinib as treatment for Bing–Neel syndrome reclassified as glioblastoma: a case report

Ibrutinib as treatment for Bing–Neel syndrome reclassified as glioblastoma: a case report

Abstract Background Glioblastoma is a highly malignant disease with limited treatment options. Ibrutinib, a covalent Bruton tyrosine kinase inhibitor, is an oral agent with manageable side effects used for hematological diseases including Waldenström macroglobulinemia. We present the case of a 69-ye...

Full description

Saved in:
Bibliographic Details
Main Authors: Charlotte Dahl Gravesen, Iman Chanchiri, Ida Bruun Kristensen, Martin Bang Jensen, Frederik Severin Gråe Harbo, Rikke Hedegaard Dahlrot
Format: Article
Language:English
Published: BMC 2024-09-01
Series:Journal of Medical Case Reports
Subjects:
Glioma
Glioblastoma
Bing–Neel syndrome
Ibrutinib
Case report
Online Access:https://doi.org/10.1186/s13256-024-04757-z
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items